```
=> s us2004167168/pn
L1             1 US2004167168/PN

=> d bib abs

L1   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2003:77336  CAPLUS
DN   138:126952
TI   Polymorphs of fexofenadine hydrochloride
IN   Dolitzky, Ben-Zion; Wizel, Shlomit; Krochmal, Barnaba; Diller, Dov; Gross,
     Irwin
PA   Israel
SO   U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U. S. Ser. No. 118,807.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 2003021849        A1    20030130    US 2002-133460          20020426
     US 2002177608        A1    20021128    US 2002-118807          20020408
     CA 2465913           A1    20030515    CA 2002-2465913         20021108
     WO 2003039482        A2    20030515    WO 2002-US35996         20021108
     WO 2003039482        A3    20031120
     WO 2003039482        A8    20050106
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002357701        A1    20030519    AU 2002-357701          20021108
     EP 1453509           A2    20040908    EP 2002-792238          20021108
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005537218        T     20051208    JP 2003-541774          20021108
     US 2004058955        A1    20040325    US 2003-661259          20030912
     US 2004167168        A1    20040826    US 2004-788924          20040225 <--
PRAI US 2001-282521P      P     20010409
     US 2001-307752P      P     20010725
     US 2001-314396P      P     20010823
     US 2001-336930P      P     20011108
     US 2001-339041P      P     20011207
     US 2001-344114P      P     20011228
     US 2002-361780P      P     20020304
     US 2002-363482P      P     20020311
     US 2002-118807       A2    20020408
     US 2002-133460       A     20020426
     US 2002-390198P      P     20020619
     US 2002-403765P      P     20020815
     US 2002-406214P      P     20020827
     US 2002-387670P      P     20021006
     WO 2002-US35996      W     20021108
AB   The present invention provides novel crystal forms of fexofenadine
     hydrochloride Forms V, VI and VIII-XV and processes for their preparation as
     well as preparation of amorphous form and other crystalline forms of
fexofenadine
     hydrochloride.  Forms XIV and XV are solvates of Et acetate, while Form IX
     is a solvate of MTBE or cyclohexane.  The forms are useful for
```

administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compns. of the new crystalline forms.

```
=> analyze l1
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
L2          ANALYZE L1 1 RN :       5 TERMS

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      16.51      17.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.78      -0.78

FILE 'REGISTRY' ENTERED AT 17:41:40 ON 22 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 JAN 2007  HIGHEST RN 917948-20-0
DICTIONARY FILE UPDATES:  21 JAN 2007  HIGHEST RN 917948-20-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s l2
L3            5 L2

=> d 1-5

L3   ANSWER 1 OF 5  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   470671-12-6  REGISTRY
ED   Entered STN:  06 Nov 2002
CN   Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-
     piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with
     cyclohexane (9CI)  (CA INDEX NAME)
DR   491600-66-9
MF   C32 H39 N O4 . x C6 H12 . Cl H
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL

     CM   1

     CRN  153439-40-8  (83799-24-0)
     CMF  C32 H39 N O4 . Cl H
```



● HCl

CM 2

CRN 110-82-7
CMF C6 H12

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2007 ACS on STN
RN 470671-11-5 REGISTRY
ED Entered STN: 06 Nov 2002
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with 2-methoxy-2-methylpropane (9CI) (CA INDEX NAME)
DR 491600-65-8
MF C32 H39 N O4 . x C5 H12 O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 1634-04-4
CMF C5 H12 O

t-Bu—O—Me

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2007 ACS on STN
RN 470671-10-4 REGISTRY
ED Entered STN: 06 Nov 2002
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with ethyl acetate (9CI) (CA INDEX NAME)
DR 491600-67-0
MF C32 H39 N O4 . x C4 H8 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 141-78-6
CMF C4 H8 O2

Et—O—Ac

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2007 ACS on STN
RN 153439-40-8 REGISTRY
ED Entered STN: 04 Mar 1994
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Allegra
CN Fexofenadine hydrochloride
CN MDL 16455A
CN Telfast
CN Telfast BD
DR 138452-21-8
MF C32 H39 N O4 . Cl H

CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (83799-24-0)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

173 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
173 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2007 ACS on STN
RN 83799-24-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylphenylacetic acid
CN Carboxyterfenadine
CN Fexofenadine
CN MDL 16455
CN Terfenadine acid metabolite
CN Terfenadine carboxylate
DR 159389-12-5, 76815-58-2
MF C32 H39 N O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

549 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
550 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l4
L4 HAS NO ANSWERS
L4 STR



Page 1-A

--O
12

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE

=> d l5 his

(FILE 'REGISTRY' ENTERED AT 17:43:05 ON 22 JAN 2007)
L5 36 SEA FILE=REGISTRY FAM FUL L4

```
                ---------
L4                STR
L5             36 SEA FILE=REGISTRY FAM FUL L4
                ---------
L6             15 S L5 AND HYDROCHLORIDE
L7              1 S  153439-40-8
L8             14 S L6 NOT L7

    FILE 'CAPLUS' ENTERED AT 17:44:13 ON 22 JAN 2007
L9             18 S L8
```

```
=> s  153439-40-8
L7             1 153439-40-8
                 (153439-40-8/RN)

=> s l6 not l7
L8            14 L6 NOT L7

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    35.10      62.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -0.78

FILE 'CAPLUS' ENTERED AT 17:44:13 ON 22 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Jan 2007  VOL 146 ISS 5
FILE LAST UPDATED: 21 Jan 2007  (20070121/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l8
L9            18 L8

=> d bib abs hitstr 1-18

L9   ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:29843  CAPLUS
DN   144:114350
TI   Fexofenadine polymorphs and process for the preparation thereof
IN   Castaldi, Graziano; Barreca, Giuseppe; Allegrini, Pietro; Ventimiglia,
     Gianpiero
PA   Dipharma S.p.A., Italy
SO   Eur. Pat. Appl., 12 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   EP 1614681           A1    20060111    EP 2005-11652           20050531
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
             BA, HR, IS, YU
```

	JP 2005350459	A	20051222	JP 2005-154155	20050526
	US 2005282860	A1	20051222	US 2005-145927	20050607
PRAI	IT 2004-MI1143	A	20040608		

AB The invention provides novel crystalline forms of fexofenadine hydrochloride, a process for the preparation of the novel forms and of the known form A, and their use in therapy. Thus, acetonitrile 2650 mL were loaded in a four-necked 3 L flask, then heated to 45° C. Fexofenadine hydrochloride hydrate 265 g was added under stirring and the suspension was refluxed at (80-82°C) for about one hour. The suspension was cooled to about -15/-10° C in about 4 h. The precipitated solid was filtered and washed with acetonitrile (2 x 80 mL) to obtain 285 g of wet product which, after drying under vacuum at 50° C for 10 h, yields fexofenadine hydrochloride monosolvate 262 g with acetonitrile.

IT 174523-28-5P 870994-52-8P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(fexofenadine polymorphs and process for preparation thereof)

RN 174523-28-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

● x H_2O

RN 870994-52-8 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, monohydrochloride, compd. with acetonitrile (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 75-05-8
CMF C2 H3 N

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1311440 CAPLUS
DN 144:57358
TI Preparation of fexofenadine polymorphs
IN Castaldi, Graziano; Barreca, Guiseppe; Ventimiglia, Gianpiero; Allegrini, Pietro
PA Dipharma S.p.A., Italy
SO Can. Pat. Appl., 17 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2509311	A1	20051208	CA 2005-2509311	20050607
	JP 2005350459	A	20051222	JP 2005-154155	20050526
	US 2005282860	A1	20051222	US 2005-145927	20050607
PRAI	IT 2004-MI1143	A	20040608		

GI



I

AB The invention provides novel crystalline forms of fexofenadine-HCl (I), a process for the preparation of the novel forms and of the known form A, and their use in therapy.

IT 870994-52-8P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fexofenadine polymorphs)

RN 870994-52-8 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, monohydrochloride, compd. with acetonitrile (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 75-05-8
CMF C2 H3 N



IT 174523-28-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fexofenadine polymorphs)
RN 174523-28-5 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

● x H_2O

L9 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1075404 CAPLUS
DN 143:353370
TI Bilayer tablet comprising an antihistamine and a decongestant
IN Patel, Ashish A.; Guo, Mintong; Matharu, Amol Singh
PA USA
SO U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005220877	A1	20051006	US 2004-815127	20040331
PRAI US 2004-815127		20040331		

OS MARPAT 143:353370
AB A pharmaceutical composition in the form of a bilayer tablet comprising: (a) a first discrete portion made with Formulation (A) which comprises a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, and a first carrier base material which provides a sustained-release of the sympathomimetic drug or the pharmaceutically acceptable salt thereof, said first carrier base material comprising a mixture of: (i) a filler; (ii) a cellulose binder selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose, and mixts. thereof, wherein the hydroxypropyl cellulose has a mol. weight of at least 80,000; (iii) ethylcellulose; (iv) a wax; and (v) a lubricant; and (b) a second discrete portion made with Formulation (B) which comprises a piperidinoalkanol

compound, or a pharmaceutically acceptable salt thereof, and a second carrier base material which provides an immediate-release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof, said second carrier base comprising a mixture of: (i)' a sugar; (ii)' a disintegrant; and (iii)' a lubricant. The bilayer tablets exhibit acceptable content uniformity under USP requirements, resist lamination and have acceptable phys. strength during the self life.

IT 174523-28-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bilayer tablet comprising antihistamine and decongestant)

RN 174523-28-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

● x H2O

L9 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:821326 CAPLUS
DN 143:229723
TI Process for optical resolution method for fexofenadine HCl salt
IN Lin, Guoqiang; Peng, Jiashi
PA Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 11 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1442407	A	20030917	CN 2003-116314	20030411
PRAI	CN 2003-116314		20030411		

OS CASREACT 143:229723; MARPAT 143:229723
GI



I



II

AB The chiral (+)- and (-)-fexofenadine HCl salt, I•HCl (R = H), were prepared by optical resolution of racemic fexofenadine alkyl esters I (R = alkyl) with chiral tartaric acid derivative, such as dibenzoyltartaric acids II•nH2O (R1, R2 = H, MeO, Cl, NO2 or CN; n = 0-3), diacetyltartaric acids or their hydrates, in organic solvent at -20-100°C to obtain chiral (+)- and (-)-fexofenadine alkyl ester; followed by hydrolysis to provide the title compound

IT 138515-56-7P 138515-57-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of chiral fexofenadine HCl salt by optical resolution of fexofenadine alkyl esters with tartaric acid derivs.)

RN 138515-56-7 CAPLUS

CN Benzeneacetic acid, 4-[(1S)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 138515-57-8 CAPLUS

CN Benzeneacetic acid, 4-[(1R)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

L9 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:238545 CAPLUS
DN 142:291446
TI Methods and kits for monitoring resistance to therapeutic agents
IN Cantor, Thomas L.
PA USA
SO U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005059023	A1	20050317	US 2003-664263	20030916
PRAI US 2003-664263		20030916		

AB The invention relates to novel methods and kits for monitoring the therapeutic inactivating capacity of a subject. The invention further relates to methods and kits for determining and/or monitoring a therapeutic protocol for a subject afflicted with auto-antibodies specific for a natural substance, wherein these auto antibodies develop as a result of therapeutic administration of the natural substance or an analog thereof. These methods and kits can be used, for example, to initiate, terminate, or adjust the level of administration of any of a variety of therapeutic agents.

IT 616242-78-5, Allegra D
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fexofenadine-pseudoephedrine mixture; methods and kits for monitoring resistance to therapeutic agents)

RN 616242-78-5 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (αS)-α-[(1S)-1-(methylamino)ethyl]benzenemethanol hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 345-78-8
CMF C10 H15 N O . Cl H

Absolute stereochemistry. Rotation (+).



● HCl

L9 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1100662 CAPLUS
DN 143:19502
TI Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit
AU Berkowitz, Robert B.; McCafferty, Frank; Lutz, Cheryl; Bazelmans, Donna; Godfrey, Penny; Meeves, Suzanne; Liao, Yuning; Georges, George
CS RxResearch, Woodstock, GA, USA
SO Allergy and Asthma Proceedings (2004), 25(5), 335-343
CODEN: AAPRFV; ISSN: 1088-5412
PB OceanSide Publications, Inc.
DT Journal
LA English
AB Although antihistamine-decongestant combinations are frequently used for allergic rhinitis, published data about the onset of action of these combination agents are limited. This randomized, double-blind, placebo-controlled, parallel-group study investigated the onset of action, efficacy, and safety of fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg or placebo in patients with moderate-to-severe seasonal allergic rhinitis in an allergen exposure unit. Assessments included major symptom complex (MSC) score (sum of sneezing, itchy nose, runny nose, watery eyes, itchy eyes, itchy ears/throat, and stuffy nose), and total symptom complex (TSC) score (MSC symptoms plus nose blows, sniffles, postnasal drip, and cough). Onset of action was defined as the first time that two consecutive, statistically significant absolute changes in MSC scores from baseline were achieved for study drug relative to placebo. The onset of action for the combination was 60 min (mean absolute MSC change from baseline: -6.9 ± 0.3 for the combination compared with -5.9 ± 0.3 for placebo from a baseline of 17.0 and 16.8, resp.; $p < 0.05$) for the modified intention-to-treat population (n = 486). Redns. in absolute MSC scores were

significantly greater with the combination than placebo at all subsequent time points ($p < 0.01$). The combination resulted in significantly greater redns. compared with placebo for percent MSC, absolute TSC, and percent TSC scores at 60 min postdose (all $p < 0.05$) and throughout the study (all $p < 0.05$). The incidence of adverse events was 1.6 and 3.3% for the combination and placebo, resp. In conclusion, fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg is effective in the treatment of patients with moderate-to-severe seasonal AR, with an onset of action of 60 min and a good safety profile.

IT 616242-78-5, Allegra-D
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fexofenadine HCl 60 mg, pseudoephedrine HCl 120 mg combination was effective with good safety profile, onset of action of 60 min in human with moderate-to-severe seasonal allergic rhinitis to ragweed allergen in allergen exposure unit)

RN 616242-78-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (αS)-α-[(1S)-1-(methylamino)ethyl]benzenemethanol hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 345-78-8
CMF C10 H15 N O . Cl H

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:148071 CAPLUS
DN 140:210225
TI Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis
AU Moinuddin, Rizwan; de Tineo, Marcy; Maleckar, Barbara; Naclerio, Robert M.; Baroody, Fuad M.
CS Section of Otolaryngology-Head and Neck Surgery, The Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA
SO Annals of Allergy, Asthma, & Immunology (2004), 92(1), 73-79
CODEN: ALAIF6; ISSN: 1081-1206
PB American College of Allergy, Asthma, & Immunology
DT Journal
LA English
AB Background: Antihistamine-decongestant combinations are used routinely for the treatment of seasonal allergic rhinitis. Recently, the combination of an antihistamine and a leukotriene receptor antagonist has been shown to be efficacious. Objective: To compare the 2 combinations in the treatment of seasonal allergic rhinitis. Methods: This was a randomized, double-blind, double-dummy, parallel study in which patients with seasonal allergic rhinitis received either fexofenadine, 60 mg, and pseudoephedrine, 120 mg, twice, daily, or loratadine, 10 mg, and montelukast, 10 mg, once daily, for 2 wk. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was completed at the beginning and end of the study. Patients recorded nasal symptoms and measured nasal peak inspiratory flow (NPIF) twice daily. Baseline measurements were obtained before initiation of treatment. Results: Compared with baseline, both treatments resulted in statistically and clin. meaningful redns. of overall and individual RQLQ domain scores ($P < .01$) except for the sleep domain, for which only loratadine-montelukast led to significant improvement. There was a significant reduction in total symptoms ($P \leq .05$) compared with baseline on most treatment days in patients receiving both combinations. When the change from baseline was analyzed, there were no statistically significant differences in total symptoms between fexofenadine-pseudoephedrine and loratadine-montelukast (median, -28.5 vs. -22.5; $P = .33$). There was a significant improvement in NPIF from baseline on all treatment days in both groups ($P < .05$), with no significant difference between treatments. Conclusions: Fexofenadine-pseudoephedrine and loratadine-montelukast have comparable efficacy in improving symptoms, RQLQ scores, and nasal obstruction in seasonal allergic rhinitis. The lack of improvement in sleep in the fexofenadine-pseudoephedrine group is probably related to insomnia, a known adverse effect of pseudoephedrine.
IT 616242-78-5, Allegra-D
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Allegra-D; fexofenadine-pseudoephedrine (Allegra D) vs. loratadine-montelukast (Singulair) in treatment of patients with seasonal allergic rhinitis)
RN 616242-78-5 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (αS)-α-[(1S)-1-(methylamino)ethyl]benzenemethanol hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 345-78-8
CMF C10 H15 N O . Cl H

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:704625 CAPLUS
DN 139:332660
TI Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit
AU Berkowitz, Robert B.; Woodworth, George G.; Lutz, Cheryl; Weiler, Kay; Weiler, John; Moss, Madelyn; Meeves, Suzanne
CS RxResearch, Woodstock, GA, USA
SO Annals of Allergy, Asthma, & Immunology (2002), 89(1), 38-45
CODEN: ALAIF6; ISSN: 1081-1206
PB American College of Allergy, Asthma, & Immunology
DT Journal
LA English
AB Background: Second-generation antihistamine-decongestant combinations are often used to treat seasonal allergies. However, onset of action and efficacy data for these agents in a controlled setting are limited. Objective: Determine onset of action of fexofenadine-pseudoephedrine (Allegra-D, Aventis, Bridgewater, NJ) for treating moderate-to-severe seasonal allergies in an allergen exposure unit. Methods: This single-dose, double-blind, placebo-controlled study was conducted during the fall ragweed allergy season. Qualifying subjects attended one to two priming visits; those with sufficient symptom scores returned for treatment and were initially exposed to ragweed pollen for 90 min. Symptomatic subjects received fexofenadine-pseudoephedrine or placebo and recorded symptoms for 6 h postdose. Efficacy variables were major symptom complex (MSC; sneezes, itchy nose, runny nose, watery eyes, itchy eyes, itchy ears/throat, stuffy nose), total symptom complex (nose blows, sniffles, postnasal drip, cough, plus all MSC symptoms), and all

individual symptoms as well as headache. Onset of action for each efficacy variable was calculated as the earliest time at which a consistent, significant decrease was seen for fexofenadine-pseudoephedrine vs. placebo. Results: Of 571 screened subjects, 298 were randomized. Onset of relief for fexofenadine-pseudoephedrine (n = 148) was 45 min postdose (MSC, P = 0.0127; total symptom complex, P = 0.0380). All individual symptoms were reduced to a greater extent with fexofenadine-pseudoephedrine than with placebo (P < 0.05, not adjusted for multiple comparisons). Decrease in headache with fexofenadine-pseudoephedrine vs. placebo began 45 min postdose (P = 0.0425). Incidence of treatment-related adverse events was 1.4% for fexofenadine-pseudoephedrine and 3.3% for placebo. Conclusions: Fexofenadine-pseudoephedrine was safe and effective in treating a broad range of allergy symptoms, with a rapid onset of action at 45 min.

IT 616242-78-5, Allegra-D
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg vs. placebo in Atlanta allergen exposure unit)

RN 616242-78-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (αS)-α-[(1S)-1-(methylamino)ethyl]benzenemethanol hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 345-78-8
CMF C10 H15 N O . Cl H

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:132338 CAPLUS
DN 138:193263
TI Drug compositions for treatment of allergic rhinitis containing fexofenadine hydrochloride and anticholinergic agents
IN Iizuka, Takao; Nakano, Kazumi; Kurachi, Michio; Nakamori, Masaru
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2003048834	A	20030221	JP 2001-233185	20010801
PRAI JP 2001-233185		20010801		

AB The compns., which suppress sneezing and running nose due to allergic rhinitis, etc., and have less sleepiness-inducing action, contain fexofenadine hydrochloride (I) and anticholinergic agents. I.p. administration of I and belladonna total alkaloids to guinea pigs strongly suppressed sneezing and running nose. Pharmaceutical prepns. containing I and belladonna alkaloids were also formulated.

IT 498547-68-5 498547-69-6 498547-70-9
498547-71-0 498547-72-1 498547-73-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug compns. containing fexofenadine hydrochloride and anticholinergic agents for treatment of symptoms of allergic rhinitis)

RN 498547-68-5 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl α-(hydroxymethyl)benzeneacetate (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 51-55-8
CMF C17 H23 N O3

Relative stereochemistry.



RN 498547-69-6 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl α-hydroxybenzeneacetate (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 87-00-3
CMF C16 H21 N O3

Relative stereochemistry.



RN 498547-70-9 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (αS)-(1α,2β,4β,5α,7β)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl α-(hydroxymethyl)benzeneacetate (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 51-34-3
CMF C17 H21 N O4

Absolute stereochemistry. Rotation (-).



RN 498547-71-0 CAPLUS
CN Benzenepropanaminium, γ-(aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-γ-phenyl-, iodide, mixt. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 71-81-8
CMF C23 H33 N2 O . I



● I^-

RN 498547-72-1 CAPLUS
CN Ethanaminium, N,N-diethyl-2-[(hydroxydiphenylacetyl)oxy]-N-methyl-, bromide, mixt. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 3166-62-9
CMF C21 H28 N O3 . Br



● Br^-

RN 498547-73-2 CAPLUS
CN 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-[2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl]-, bromide, mixt. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid hydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 50-34-0
CMF C23 H30 N O3 . Br



● Br^-

L9 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:77336 CAPLUS
DN 138:126952
TI Polymorphs of fexofenadine hydrochloride
IN Dolitzky, Ben-Zion; Wizel, Shlomit; Krochmal, Barnaba; Diller, Dov; Gross, Irwin
PA Israel
SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U. S. Ser. No. 118,807.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003021849	A1	20030130	US 2002-133460	20020426
	US 2002177608	A1	20021128	US 2002-118807	20020408
	CA 2465913	A1	20030515	CA 2002-2465913	20021108
	WO 2003039482	A2	20030515	WO 2002-US35996	20021108
	WO 2003039482	A3	20031120		
	WO 2003039482	A8	20050106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2002357701	A1	20030519	AU 2002-357701	20021108
	EP 1453509	A2	20040908	EP 2002-792238	20021108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005537218	T	20051208	JP 2003-541774	20021108
	US 2004058955	A1	20040325	US 2003-661259	20030912
	US 2004167168	A1	20040826	US 2004-788924	20040225
PRAI	US 2001-282521P	P	20010409		
	US 2001-307752P	P	20010725		
	US 2001-314396P	P	20010823		
	US 2001-336930P	P	20011108		
	US 2001-339041P	P	20011207		
	US 2001-344114P	P	20011228		
	US 2002-361780P	P	20020304		
	US 2002-363482P	P	20020311		
	US 2002-118807	A2	20020408		
	US 2002-133460	A	20020426		
	US 2002-390198P	P	20020619		
	US 2002-403765P	P	20020815		
	US 2002-406214P	P	20020827		
	US 2002-387670P	P	20021006		
	WO 2002-US35996	W	20021108		

AB The present invention provides novel crystal forms of fexofenadine hydrochloride Forms V, VI and VIII-XV and processes for their preparation as well as preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms XIV and XV are solvates of Et acetate, while Form IX is a solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compns. of the new crystalline forms.

IT 470671-10-4P 470671-11-5P 470671-12-6P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polymorphs of fexofenadine hydrochloride for use as antihistaminic)

RN 470671-10-4 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with ethyl acetate (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 141-78-6

CMF C4 H8 O2

Et—O—Ac

RN 470671-11-5 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with 2-methoxy-2-methylpropane (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 1634-04-4
CMF C5 H12 O

t-Bu—O—Me

RN 470671-12-6 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with cyclohexane (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 110-82-7
CMF C6 H12

L9 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:793365 CAPLUS
DN 137:316066
TI Polymorphs of fexofenadine hydrochloride
IN Dolitzky, Ben-Zion; Wizel, Shlomit; Krochmal, Barnaba; Diller, Dov; Gross, Irwin
PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080857	A2	20021017	WO 2002-US11251	20020408
	WO 2002080857	A3	20031218		
	WO 2002080857	A8	20040527		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2444456	A1	20021017	CA 2002-2444456	20020408
	AU 2002305162	A1	20021021	AU 2002-305162	20020408
	EP 1392303	A2	20040303	EP 2002-733966	20020408
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-282521P	P	20010409		
	US 2001-307752P	P	20010725		
	US 2001-314396P	P	20010823		
	US 2001-336930P	P	20011108		
	US 2001-339041P	P	20011207		
	US 2001-344114P	P	20011228		
	US 2002-361780P	P	20020304		
	US 2002-363482P	P	20020311		
	WO 2002-US11251	W	20020408		

AB The present invention provides novel crystal forms of fexofenadine hydrochloride Forms (V, VI and VIII through XV) and processes for their preparation and preparation of amorphous form and other crystalline forms of fexofenadine hydrochloride. Forms (XIV and XV) are solvates of Et acetate, while Form IX is anhydrous, but can be crystallized as solvate of MTBE or cyclohexane. The forms are useful for administration to humans and animals to alleviate symptoms caused by histamine. The present invention further provides pharmaceutical compns. of the new crystalline forms, e.g., capsules and

tablets.

IT 470671-10-4 470671-11-5 470671-12-6
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(preparation of polymorphs of fexofenadine hydrochloride for antihistaminic compns.)

RN 470671-10-4 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with ethyl acetate (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 141-78-6
CMF C4 H8 O2

Et—O—Ac

RN 470671-11-5 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with 2-methoxy-2-methylpropane (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 1634-04-4
CMF C5 H12 O

t-Bu—O—Me

RN 470671-12-6 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with cyclohexane (9CI) (CA INDEX NAME)

CM 1

CRN 153439-40-8
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 110-82-7
CMF C6 H12

L9 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:833069 CAPLUS
DN 135:376743
TI Packaging regimen of pseudoephedrine and fexofenadine
IN Randall, Douglas E.; Nicholas, James M.
PA Aventis Pharmaceuticals Inc., USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085148	A2	20011115	WO 2001-US14353	20010503
	WO 2001085148	A3	20020801		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2001061165	A5	20011120	AU 2001-61165	20010503
	US 2002022639	A1	20020221	US 2001-848463	20010503
	JP 2003532671	T	20031105	JP 2001-581802	20010503
PRAI	US 2000-202323P	P	20000505		
	GB 2000-30802	A	20001218		
	WO 2001-US14353	W	20010503		

AB A package for dispensing 2 or more drugs is described and claimed. In one of the embodiments of this invention, the package dispenses essentially: a container to dispense drug (A) having therapeutically effective amts. of fexofenadine or its salt; and a container to dispense drug (B) containing a combination of fexofenadine and pseudoephedrine or their salts. Various preferred embodiments of the package of this invention are also described and claimed. Thus, the package of a bilayer tablet comprises a first discrete zone containing 25-33% pseudoephedrine, and a a first carrier base material. The first carrier base material comprises a mixture of carnauba wax 66-74% and a suitable antiadherent 0.50-1.50 by weight of pseudoephedrine.

IT 174523-28-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(packaging regimen of pseudoephedrine and fexofenadine)

RN 174523-28-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

●x H2O

L9 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:186719 CAPLUS

DN 132:227453

TI Sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants

IN Maclaren, David D.; Lefler, John R.; Minish, Sharon K.

PA Hoechst Marion Roussel, Inc., USA

SO U.S., 15 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 6039974 A 20000321 US 1998-127478 19980731
PRAI US 1997-90105 P 19970826

AB A pharmaceutical composition in the form of a bilayer tablet is provided comprising, (a) a first discrete zone made with formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of; (i) carnauba wax in an amount of about 59% to about 81% by weight of formulation (A); and (ii) a suitable antiadherent in an amount of about 0.25% to about 2.00% by weight of formulation (A). Wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and (b) a second discrete zone made with formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol, or a pharmaceutically acceptable salt thereof, in an amount of about 15% to about 30% by weight of formulation (B) and a second carrier base material, the second carrier base comprising a mixture of; (i) a cellulose diluent in an amount of about 27% to about 73% by weight of formulation (B); (ii) pregelatinized starch in an amount of about 15% to about 30% by weight of formulation (B); (iii) a suitable disintegrant in an amount of about 0.25% to about 6.00% by weight of formulation (B); and (iv) a suitable lubricant in an amount of about 0.25% to about 2.00% by weight of formulation (B); wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof. A bilayer tablet contained 4[4[4(Hydroxydiphenylmethyl)-1-piperdinyl]-1-hydroxybutyl] dimethylbenzeneacetic acid hydrochloride 60.00, microcryst. cellulose 26.00, pregelatinized starch 60.00, microcryst. cellulose (Avicel PH 102) 190.5, croscarmellose sodium 12.00, magnesium stearate 2.633 mg in the immediate-release layer; pseudoephedrine hydrochloride 120.0, carnauba wax 300.0, stearic acid flakes 4.899, colloidal silicon dioxide 1.065, and Opadry YS-17006 23.31 mg in the sustained-release layer.

IT 174523-28-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release pharmaceutical tablets containing combination of piperidinoalkanols and decongestants)

RN 174523-28-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

● x H2O

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:676324 CAPLUS

DN 130:60560
TI Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers
AU Robbins, Doris K.; Castles, Mark A.; Pack, David J.; Bhargava, Vijay O.; Weir, Scott J.
CS North America Pharmacokinetics and Biometrics Dep., Hoechst Marion Roussel, Inc., Kansas City, MO, USA
SO Biopharmaceutics & Drug Disposition (1998), 19(7), 455-463
CODEN: BDDID8; ISSN: 0142-2782
PB John Wiley & Sons Ltd.
DT Journal
LA English
AB The pharmacokinetics and dose proportionality of fexofenadine, a new non-sedating antihistamine, and its enantiomers were characterized after single and multiple-dose administration of its hydrochloride salt. A total of 24 healthy male volunteers (31 ± 8 yr) received oral doses of 20, 60, 120 and 240 mg fexofenadine HCl in a randomized, complete four-period cross-over design. Subjects received a single oral dose on day 1, and multiple oral doses every 12 h on day 3 through the morning on day 7. Treatments were separated by a 14-day washout period. Serial blood and urine samples were collected for up to 48 h following the first and last doses of fexofenadine HCl. Fexofenadine and its R(+) and S(-) enantiomers were analyzed in plasma and urine by validated HPLC methods. Fexofenadine pharmacokinetics were linear across the 20-120 mg dose range, but a small disproportionate increase in area under the plasma concentration-time curve (AUC) (<25%) was observed following the 240 mg dose. Single-dose pharmacokinetics of fexofenadine were predictive of steady-state pharmacokinetics. Urinary elimination of fexofenadine played a minor role (10%) in the disposition of the drug. A 63.37 steady-state ratio of R(+) and S(-) fexofenadine was observed in plasma. This ratio was essentially constant across time and dose. R(+) and S(-) fexofenadine were eliminated into urine in equal rates and quantities. All doses of fexofenadine HCl were well tolerated after single and multiple-dose administration.
IT 138515-56-7 138515-57-8
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(fexofenadine and its enantiomers pharmacokinetics in humans)
RN 138515-56-7 CAPLUS
CN Benzeneacetic acid, 4-[(1S)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 138515-57-8 CAPLUS
CN Benzeneacetic acid, 4-[(1R)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:702047 CAPLUS
DN 126:11543
TI Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
IN Ortyl, Thomas T.; Skultety, Paul F.; Hurst, Gail H.
PA Hoechst Marion Roussel, Inc., USA
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5574045	A	19961112	US 1995-469392	19950606
	CA 2218643	A1	19961212	CA 1996-2218643	19960430
	CA 2218643	C	20011211		
	WO 9639139	A1	19961212	WO 1996-US5968	19960430
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9656695	A	19961224	AU 1996-56695	19960430
	AU 707218	B2	19990708		
	EP 831820	A1	19980401	EP 1996-913862	19960430
	EP 831820	B1	20031217		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	CN 1187125	A	19980708	CN 1996-194495	19960430
	HU 9802096	A2	19990128	HU 1998-2096	19960430
	JP 11506115	T	19990602	JP 1996-500501	19960430
	AT 256465	T	20040115	AT 1996-913862	19960430
	PT 831820	T	20040531	PT 1996-913862	19960430
	ES 2211954	T3	20040716	ES 1996-913862	19960430

	ZA 9604517	A	19961209	ZA 1996-4517	19960531
	TW 460283	B	20011021	TW 1996-85106573	19960601
	IL 118525	A	20010724	IL 1996-118525	19960602
	NO 9705680	A	19980205	NO 1997-5680	19971205
	NO 318029	B1	20050124		
PRAI	US 1995-469392	A	19950606		
	WO 1996-US5968	W	19960430		

OS MARPAT 126:11543

AB The present invention provides an oral pharmaceutical composition in solution form, comprising (a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof and (b) a suitable solvent system comprising propylene glycol and glacial acetic acid, to provide efficient and immediate absorption and bioavailability. The piperidinoalkanol compds. are known as antihistaminies, allergy inhibitors, and bronchodilators (no data). The preferred compound is 4-[4-[4- (hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid·HCl (I). I 1.125 g was dissolved in 40 mL of a solvent system containing 98.5% propylene glycol and 1.5% glacial acetic acid and after dissoln. was complete, the total volume of the solution was made to 50 mL to provide an oral composition in solution form with a strength of 22.5 mg/mL.

IT 174523-28-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral solns. containing piperidinoalkanols)

RN 174523-28-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

●x H2O

L9 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1996:656431 CAPLUS

DN 125:285021

TI Pharmaceutical composition for piperidinoalkanol compounds

IN Ortyl, Thomas T.; Skultety, Paul F.; Mitchell, Kristen C.; Phadke, Deepak S.; Attarchi, Faraneh; Pierce, Marguerite L.; Schoeneman, Aaron W.; Schnitz, Joseph M.

PA Hoechst Marion Roussel, Inc., USA

SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9626726	A1	19960906	WO 1996-US1253	19960126

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN

CA 2213700	A1	19960906	CA 1996-2213700	19960126
CA 2213700	C	20020402		
AU 9649098	A	19960918	AU 1996-49098	19960126
AU 701042	B2	19990121		
EP 812195	A1	19971217	EP 1996-905292	19960126
EP 812195	B1	20021030		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV

CN 1176599	A	19980318	CN 1996-192200	19960126
CN 1090935	B	20020918		
JP 11501028	T	19990126	JP 1996-526257	19960126
HU 9802086	A2	19990128	HU 1998-2086	19960126
AT 226819	T	20021115	AT 1996-905292	19960126
ES 2181868	T3	20030301	ES 1996-905292	19960126
PT 812195	T	20030331	PT 1996-905292	19960126
ZA 9601389	A	19960828	ZA 1996-1389	19960221
IL 117237	A	20010111	IL 1996-117237	19960223
TW 460284	B	20011021	TW 1996-85102075	19960223
IL 134769	A	20020210	IL 1996-134769	19960223
IL 134770	A	20020210	IL 1996-134770	19960223
IL 134771	A	20020210	IL 1996-134771	19960223
IL 134772	A	20020210	IL 1996-134772	19960223
US 5738872	A	19980414	US 1996-742166	19961101
FI 9703518	A	19970827	FI 1997-3518	19970827
NO 9703938	A	19971028	NO 1997-3938	19970827
US 5855912	A	19990105	US 1997-943460	19971003
US 5932247	A	19990803	US 1997-948005	19971009
US 6113942	A	20000905	US 1998-157841	19980921
US 2001022973	A1	20010920	US 2001-845966	20010430
US 2002106405	A1	20020808	US 2002-39798	20020104
US 2003203020	A1	20031030	US 2003-347953	20030121
JP 2004292459	A	20041021	JP 2004-170680	20040609

PRAI US 1995-395952	A	19950228	
US 1995-552287	A	19951212	
JP 1996-526257	A3	19960126	
WO 1996-US1253	W	19960126	
IL 1996-117237	A3	19960223	
US 1996-742166	A3	19961101	
US 1997-943460	A3	19971003	
US 1998-157841	A1	19980921	
US 2000-586743	A1	20000602	
US 2001-845966	B1	20010430	
US 2002-39798	B1	20020104	

GI



I

AB The invention provides a pharmaceutical composition in solid unit dosage from, comprising, (a) a therapeutically effective amount of a piperidinoalkanol compound (I) or a pharmaceutically acceptable salt thereof; and, (b) at least one inert ingredient.

IT 174523-28-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition for piperidinoalkanol compds.)
RN 174523-28-5 CAPLUS
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

● x H2O

L9 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:170750 CAPLUS
DN 124:202030
TI Processes for preparing anhydrous and hydrate of antihistaminic piperidine derivatives (polymorphs and pseudomorphs).
IN Henton, Daniel R.; Mccarty, Frederick J.; Tripp, Susan I.; Dewitt, Jill E.
PA Marion Merrell Dow Inc., USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9531437	A1	19951123	WO 1995-US4942	19950428
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2189007	A1	19951123	CA 1995-2189007	19950428
	CA 2189007	C	20040302		
	CA 2449419	A1	19951123	CA 1995-2449419	19950428
	AU 9524265	A	19951205	AU 1995-24265	19950428
	AU 693892	B2	19980709		
	EP 766668	A1	19970409	EP 1995-918278	19950428
	EP 766668	B1	20020717		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1148849	A	19970430	CN 1995-193122	19950428
	HU 76134	A2	19970630	HU 1996-3167	19950428
	JP 10500134	T	19980106	JP 1995-529654	19950428
	EP 1178041	A1	20020206	EP 2001-124314	19950428
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 220667	T	20020815	AT 1995-918278	19950428
	JP 2002255935	A	20020911	JP 2002-55432	19950428

	JP 2002255936	A	20020911	JP 2002-55434	19950428
	JP 2002308849	A	20021023	JP 2002-55431	19950428
	JP 2002308850	A	20021023	JP 2002-55433	19950428
	JP 2002316978	A	20021031	JP 2002-55435	19950428
	PT 766668	T	20021129	PT 1995-918278	19950428
	ES 2176329	T3	20021201	ES 1995-918278	19950428
	CN 1623985	A	20050608	CN 2003-10100765	19950428
	ZA 9503930	A	19960117	ZA 1995-3930	19950515
	IL 113747	A	20010520	IL 1995-113747	19950516
	IL 134917	A	20010724	IL 1995-134917	19950516
	FI 9604565	A	19961114	FI 1996-4565	19961114
	NO 9604859	A	19961115	NO 1996-4859	19961115
	NO 315319	B1	20030818		
	US 2001012896	A1	20010809	US 2001-803389	20010309
	US 2001014741	A1	20010816	US 2001-803390	20010309
	US 2001025106	A1	20010927	US 2001-803476	20010309
	US 2003045722	A1	20030306	US 2002-125094	20020418
	US 2002193600	A1	20021219	US 2002-128926	20020424
	US 2002193601	A1	20021219	US 2002-160883	20020603
	US 7135571	B2	20061114		
	US 2002193603	A1	20021219	US 2002-162011	20020603
	US 7138524	B2	20061121		
	US 2003045721	A1	20030306	US 2002-214262	20020807
	US 2004014976	A1	20040122	US 2003-386812	20030310
	US 2005090528	A1	20050428	US 2004-988629	20041116
PRAI	US 1994-245731	A	19940518		
	US 1995-417161	A	19950411		
	CA 1995-2189007	A3	19950428		
	EP 1995-918278	A3	19950428		
	JP 1995-529654	A3	19950428		
	WO 1995-US4942	W	19950428		
	US 1995-439671	B1	19950512		
	US 1995-439673	B1	19950512		
	IL 1995-113747	A3	19950516		
	US 1995-442460	B1	19950516		
	US 1997-815640	B1	19970313		
	US 1997-815641	B1	19970313		
	US 1997-815642	B1	19970313		
	US 1997-818087	B1	19970314		
	US 1997-899843	B1	19970724		
	US 1998-213161	B1	19981217		
	US 1998-213162	A1	19981217		
	US 1998-213554	B1	19981217		
	US 1998-213565	B1	19981217		
	US 1999-276069	B1	19990325		
	US 2000-653082	A1	20000831		
	US 2001-803389	A1	20010309		
	US 2001-803390	B1	20010309		
	US 2001-803476	A1	20010309		
	US 2002-125094	A1	20020418		
	US 2002-128926	B1	20020424		

OS MARPAT 124:202030

GI



I

AB Polymorphic and pseudomorphic title compound I [R1 = H, OH; R2 = H; R1R2 = bond; R3 = CH2OH, COOH, COOalkyl; W = CH(OH), CO; A = H, OH; Y = acid; n = 1-5], useful as antihistamines, antiallergic agents and bronchodilators, were prepared Treatment of I [R1 = OH; R2 = H; R3 = COOEt; W = CO; A = H; Y = HCl; n = 3] in MeOH with NaBH4 and NaOH/H2O afforded I.xH2O [R1 = OH; R2 = H; R3 = COOH; W = CH(OH); A = H; Y = HCl; n = 3] which was transformed into its anhydrous form by treatment with MeCOEt. Compds. I [R1 = OH; R2 = H; R3 = COOH; W = CO, CH(OH); A = H; Y = HCl; n = 3], polymorphs and pseudomorphs, are effective at 0.01-20 mg/kg per day.

IT 174523-28-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(processes for preparing anhydrous and hydrate of antihistaminic piperidine derivs. (polymorphs and pseudomorphs).)

RN 174523-28-5 CAPLUS

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)



● HCl

● x H_2O

L9 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:50726 CAPLUS

DN 116:50726

TI Direct enantiomeric separation of terfenadine and its major acid metabolite by high-performance liquid chromatography, and the lack of stereoselective terfenadine enantiomer biotransformation in man

AU Chan, Kenneth Y.; George, Ronald C.; Chen, Teng Man; Okerholm, Richard A.

CS Marion Merrell Dow Inc., Cincinnati, OH, 45215-6300, USA

SO Journal of Chromatography (1991), 571(1-2), 291-7
CODEN: JOCRAM; ISSN: 0021-9673

DT Journal

LA English

AB Direct enantiomeric separation of terfenadine and its major acid metabolite was achieved by using two different chiral stationary phase columns with two different mobile phase systems. Further, the enantiomeric composition of the human urinary acid metabolite has been determined, indicating a nonstereoselective biotransformation in man.

IT 138515-56-7, (-)-(S)-MDL 16455 138515-57-8, (+)-(R)-MDL 16455
RL: PROC (Process)
(enantiomeric separation of, as terfenadine metabolite, in human urine by HPLC)

RN 138515-56-7 CAPLUS

CN Benzeneacetic acid, 4-[(1S)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-

piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 138515-57-8 CAPLUS
CN Benzeneacetic acid, 4-[(1R)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

=> STR 153439-40-8

WARNING. SINGLE ATOM FRAGMENTS NOT INCLUDED IN MODEL:
Cl
:END

L2 STRUCTURE CREATED

=> S L2 FAM FUL

FULL SEARCH INITIATED 16:48:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 74 TO ITERATE

100.0% PROCESSED 74 ITERATIONS 36 ANSWERS
SEARCH TIME: 00.00.01

L3 36 SEA FAM FUL L2

=>

=> D SCAN

L3 36 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C32 H39 N O4 . x C4 H9 N O3

CM 1



CM 2

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d 1-36

L3 ANSWER 1 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 917472-26-5 REGISTRY
ED Entered STN: 16 Jan 2007
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH

MF C32 H39 N O4 . x C4 H9 N O3
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 72-19-5
CMF C4 H9 N O3

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 885946-90-7 REGISTRY
ED Entered STN: 29 May 2006
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, dihydrate (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . 2 H2 O
SR CA
LC STN Files: CA, CAPLUS
CRN (83799-24-0)





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 885946-89-4 REGISTRY
ED Entered STN: 29 May 2006
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, compd. with methanol (1:2) (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . 2 C H4 O
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 67-56-1
CMF C H4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 870994-52-8 REGISTRY
ED Entered STN: 03 Jan 2006
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, monohydrochloride, compd. with acetonitrile (1:1) (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . C2 H3 N . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 75-05-8
CMF C2 H3 N



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 5 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 865811-63-8 REGISTRY
ED Entered STN: 21 Oct 2005
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrate (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . x H2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (83799-24-0)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 6 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 863713-87-5 REGISTRY
ED Entered STN: 23 Sep 2005
CN β-Cyclodextrin, compd. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C42 H70 O35 . x C32 H39 N O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 83799-24-0

CMF C32 H39 N O4



CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 7 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 857085-75-7 REGISTRY
ED Entered STN: 26 Jul 2005
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-

piperidinyl]butyl]-α,α-dimethyl-, mixt. with (αS)-α-[(1S)-1-(methylamino)ethyl]benzenemethanol (9CI) (CA INDEX NAME)

FS STEREOSEARCH
MF C32 H39 N O4 . C10 H15 N O
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 90-82-4
CMF C10 H15 N O

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 8 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 847360-79-6 REGISTRY
ED Entered STN: 28 Mar 2005
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, acetate (salt) (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 64-19-7
CMF C2 H4 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 9 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 847360-78-5 REGISTRY
ED Entered STN: 28 Mar 2005
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, acetate (salt), dihydrate (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . C2 H4 O2 . 2 H2 O
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 64-19-7
CMF C2 H4 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 10 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 847360-77-4 REGISTRY
ED Entered STN: 28 Mar 2005
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, acetate (salt), monohydrate (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . C2 H4 O2 . H2 O
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 64-19-7
CMF C2 H4 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 11 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 847360-76-3 REGISTRY
ED Entered STN: 28 Mar 2005
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, monohydrate (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . H2 O
SR CA
LC STN Files: CA, CAPLUS
CRN (83799-24-0)



● H_2O

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 12 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 616242-78-5 REGISTRY
ED Entered STN: 13 Nov 2003
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (αS)-α-[(1S)-1-(methylamino)ethyl]benzenemethanol hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Allegra D
FS STEREOSEARCH
MF C32 H39 N O4 . C10 H15 N O . 2 Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 345-78-8 (90-82-4)
CMF C10 H15 N O . Cl H

Absolute stereochemistry. Rotation (+).



● HCl

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 13 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 586349-05-5 REGISTRY
ED Entered STN: 16 Sep 2003

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, nitrate (salt) (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . H N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 14 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 548783-71-7 REGISTRY
ED Entered STN: 16 Jul 2003
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-di(methyl-d3)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Fexofenadine-d6
MF C32 H33 D6 N O4
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 15 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 524713-23-3 REGISTRY
ED Entered STN: 03 Jun 2003

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, potassium salt (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . x K
SR CA
LC STN Files: CA, CAPLUS
CRN (83799-24-0)



●x K

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 16 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 524713-22-2 REGISTRY
ED Entered STN: 03 Jun 2003
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, sodium salt (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . x Na
SR CA
LC STN Files: CA, CAPLUS
CRN (83799-24-0)



●x Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 17 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 498547-73-2 REGISTRY
ED Entered STN: 13 Mar 2003
CN 2-Propanaminium, N-methyl-N-(1-methylethyl)-N-[2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl]-, bromide, mixt. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid hydrochloride (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . C23 H30 N O3 . Br . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 50-34-0 (298-50-0)
CMF C23 H30 N O3 . Br



● Br^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 18 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 498547-72-1 REGISTRY
ED Entered STN: 13 Mar 2003
CN Ethanaminium, N,N-diethyl-2-[(hydroxydiphenylacetyl)oxy]-N-methyl-, bromide, mixt. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid hydrochloride (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . C21 H28 N O3 . Br . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 3166-62-9 (13473-61-5)
CMF C21 H28 N O3 . Br



● Br^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 19 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 498547-71-0 REGISTRY
ED Entered STN: 13 Mar 2003
CN Benzenepropanaminium, γ-(aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-γ-phenyl-, iodide, mixt. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid hydrochloride (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . C23 H33 N2 O . Cl H . I
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 71-81-8 (7492-32-2)
CMF C23 H33 N2 O . I



● I^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 20 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 498547-70-9 REGISTRY
ED Entered STN: 13 Mar 2003
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (αS)-(1α,2β,4β,5α,7β)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl α-(hydroxymethyl)benzeneacetate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H39 N O4 . C17 H21 N O4 . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 51-34-3
CMF C17 H21 N O4

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 21 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 498547-69-6 REGISTRY
ED Entered STN: 13 Mar 2003
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl α-hydroxybenzeneacetate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H39 N O4 . C16 H21 N O3 . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 87-00-3
CMF C16 H21 N O3

Relative stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 22 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 498547-68-5 REGISTRY
ED Entered STN: 13 Mar 2003
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, mixt. with (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl α-(hydroxymethyl)benzeneacetate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H39 N O4 . C17 H23 N O3 . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 51-55-8
CMF C17 H23 N O3

Relative stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 23 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 470671-12-6 REGISTRY
ED Entered STN: 06 Nov 2002
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with cyclohexane (9CI) (CA INDEX NAME)
DR 491600-66-9
MF C32 H39 N O4 . x C6 H12 . Cl H

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 110-82-7
CMF C6 H12

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 24 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 470671-11-5 REGISTRY
ED Entered STN: 06 Nov 2002
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with 2-methoxy-2-methylpropane (9CI) (CA INDEX NAME)
DR 491600-65-8
MF C32 H39 N O4 . x C5 H12 O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 1634-04-4
CMF C5 H12 O

t-Bu—O—Me

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 25 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 470671-10-4 REGISTRY
ED Entered STN: 06 Nov 2002
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, compd. with ethyl acetate (9CI) (CA INDEX NAME)
DR 491600-67-0
MF C32 H39 N O4 . x C4 H8 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 153439-40-8 (83799-24-0)
CMF C32 H39 N O4 . Cl H



● HCl

CM 2

CRN 141-78-6
CMF C4 H8 O2

Et—O—Ac

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 26 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 181299-81-0 REGISTRY
ED Entered STN: 26 Sep 1996
CN β-Cyclodextrin, compd. with 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, compd. with β-cyclodextrin (1:1) (9CI)
FS STEREOSEARCH
MF C42 H70 O35 . C32 H39 N O4
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH

CM 1

CRN 83799-24-0
CMF C32 H39 N O4



CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 27 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 174523-28-5 REGISTRY
ED Entered STN: 26 Mar 1996
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, hydrate (9CI) (CA INDEX NAME)
MF C32 H39 N O4 . Cl H . x H2 O
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPAT2, USPATFULL
CRN (83799-24-0)



● HCl

● x H_2O

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 28 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 174483-05-7 REGISTRY
ED Entered STN: 22 Mar 1996
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [R-(R*,R*)]-, compd. with (S)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, (S)-, [R-(R*,R*)]-2,3-bis[(4-methylbenzoyl)oxy]butanedioate (1:1) (salt) (9CI)
FS STEREOSEARCH
MF C32 H39 N O4 . C20 H18 O8
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

CM 1

CRN 139965-11-0
CMF C32 H39 N O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 32634-66-5
CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 29 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 174483-04-6 REGISTRY
ED Entered STN: 22 Mar 1996
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [S-(R*,R*)]-, compd. with (R)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethylbenzeneacetic acid (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, (R)-, [S-(R*,R*)]-2,3-bis[(4-methylbenzoyl)oxy]butanedioate (1:1) (salt) (9CI)
FS STEREOSEARCH
MF C32 H39 N O4 . C20 H18 O8
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

CM 1

CRN 139965-10-9
CMF C32 H39 N O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 32634-68-7
CMF C20 H18 O8

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 30 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 166759-34-8 REGISTRY
ED Entered STN: 24 Aug 1995
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl-1-t]-α,α-dimethyl- (9CI) (CA INDEX NAME)
MF C32 H38 N O4 T
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 31 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 153439-40-8 REGISTRY
ED Entered STN: 04 Mar 1994
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Allegra
CN Fexofenadine hydrochloride
CN MDL 16455A
CN Telfast
CN Telfast BD
DR 138452-21-8
MF C32 H39 N O4 . Cl H
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (83799-24-0)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

173 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
173 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 32 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 139965-11-0 REGISTRY
ED Entered STN: 27 Mar 1992
CN Benzeneacetic acid, 4-[(1S)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, (S)-
OTHER NAMES:
CN (S)-Fexofenadine
FS STEREOSEARCH
MF C32 H39 N O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 33 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 139965-10-9 REGISTRY
ED Entered STN: 27 Mar 1992
CN Benzeneacetic acid, 4-[(1R)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, (R)-
OTHER NAMES:
CN (R)-Fexofenadine
FS STEREOSEARCH
MF C32 H39 N O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 34 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 138515-57-8 REGISTRY
ED Entered STN: 24 Jan 1992
CN Benzeneacetic acid, 4-[(1R)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, (R)-
OTHER NAMES:
CN (+)-(R)-MDL 16455A
FS STEREOSEARCH
MF C32 H39 N O4 . Cl H
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSPATENTS, IMSRESEARCH, TOXCENTER
CRN (139965-10-9)

Absolute stereochemistry. Rotation (+).



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 35 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 138515-56-7 REGISTRY
ED Entered STN: 24 Jan 1992
CN Benzeneacetic acid, 4-[(1S)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl-, hydrochloride, (S)-
OTHER NAMES:
CN (-)-(S)-MDL 16455A
FS STEREOSEARCH
MF C32 H39 N O4 . Cl H
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSPATENTS, IMSRESEARCH, TOXCENTER
CRN (139965-11-0)

Absolute stereochemistry. Rotation (-).



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 36 OF 36 REGISTRY COPYRIGHT 2007 ACS on STN
RN 83799-24-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzeneacetic acid, 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylphenylacetic acid
CN Carboxyterfenadine
CN Fexofenadine
CN MDL 16455
CN Terfenadine acid metabolite
CN Terfenadine carboxylate
DR 159389-12-5, 76815-58-2
MF C32 H39 N O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

549 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
550 REFERENCES IN FILE CAPLUS (1907 TO DATE)